CytoGenix Announces Successful Completion of Pre-Clinical Anti-Herpes Safety Studies.

HOUSTON -- CytoGenix, Inc. (OTCBB:CYGX) announced the successful completion of pre-clinical animal safety studies. These standard studies show that the company's lead DNA anti-herpes topical compound is safe in three species of animals. A third party laboratory conducted the tests operating under FDA Good Laboratory Practices (GLP) regulations and following United States Pharmacopeia (USP) testing standards for topical products.

Dr. Malcolm Skolnick, CytoGenix, Chairman and CEO, states "We are keenly aware of the urgent need for this product. This accomplishment brings us one-step closer to obtaining FDA authorization to conduct clinical trials of our anti-herpes cream. Rarely does a week go by without receiving an email or telephone call from a herpes sufferer contacting us about the availability of this product. Our anti-herpes cream is designed to be effective against both labial (cold sores) and genital herpes."

Genital herpes is an epidemic in the US and other parts of the world reports the US Centers for Disease Control (CDC) "Genital herpes--herpes simplex virus type two (HSV-2)--is one of the most common sexually transmitted diseases in the United States, with as many as one million people becoming infected each year. While genital herpes continues to spread across all social, economic, racial and ethnic boundaries, prevalence of infection increased most dramatically in teens and young adults. The disease is potentially fatal in newborns and is a major cause of infant blindness. Herpetic infections increase the risk of contracting HIV and can be particularly severe in people with HIV infection. HSV-2 infection is more common in women (approximately one out of four women) than in men (almost one out of five)."

CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis, anti-inflammatory topical creams and antibacterial compounds. The company owns a US patent for its core DNA expression technology and has over 40 international or US pending patent applications.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.